ArticleESMO open2026
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIMvigor010 demonstrated potential for circulating tumor DNA (ctDNA) to guide treatment in muscle-invasive urothelial carcinoma (MIUC), in which adjuvant atezolizumab (AA) reduced the risk of death by approximately 40% in ctDNA-positive patients. However, ctDNA-negative patients received no survival benefit from AA and had higher rates of immune-related adverse events (irAEs). Here, we further explore the relationship between ctDNA and irAEs. PATIENTS AND
methodsAssociation between baseline (BL) and on-treatment (OT) ctDNA and time to first irAE was assessed in MIUC patients treated with AA (n = 384) versus observation (n = 397). Cox proportional hazard model was used with adjustment for BL covariates, sensitivity analyses were carried out at 6 months to address survival bias, and landmark analysis was carried out at day (D) 43 for patients with OT ctDNA.
resultsAll grade irAE rates were higher in AA patients with negative BL ctDNA versus positive (54.7% versus 32.5%, respectively) and mainly driven by low-grade irAEs [hazard ratio (HR) 1.91 (1.25; 2.90)]. irAE rates decreased with increasing ctDNA levels as a continuous variable [ctDNA log-MTM/ml: HR 0.92 (0.87; 0.97)]. There was no association with BL ctDNA and high-grade irAEs [HR 0.87 (0.38; 1.98)], but discontinuation for AEs was higher in BL ctDNA-negative patients versus positive (3.3% versus 0%). Patients who cleared OT ctDNA after D43 had no association between ctDNA and irAEs versus non-clearance [HR 1.13 (0.35; 3.59)]. Patients who progressed to positive ctDNA after D43 did not experience any irAEs versus non-progressors.
conclusionsLow-grade irAEs and discontinuation due to AEs were higher in ctDNA-negative patients receiving AA despite the lack of a survival benefit. Continued evaluation of the potential role of ctDNA is warranted, as it may help identify patients who may be curable with only local therapy and where additional systemic treatment may only increase toxicity without improving survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.